Novocure reported that its wearable device Optune Pax, which delivers Tumor Treating Fields, has received a CE Mark to treat adult patients with locally advanced pancreatic cancer of exocrine origin when used with gemcitabine and nab-paclitaxel in line with guideline recommendations. The approval is backed by the Phase 3 PANOVA-3 trial, where patients in the intent-to-treat group receiving Optune Pax plus chemotherapy achieved a median overall survival of 16.2 months versus 14.2 months on chemotherapy alone, and a significant 6.1‑month extension in median time to pain progression. In the modified intent-to-treat group, median overall survival reached 18.3 months with Optune Pax versus 15.1 months on chemotherapy alone. Optune Pax was generally well-tolerated, with mainly mild to moderate skin events and no device-related deaths reported.
Novocure reported topline data from its Phase 3 TRIDENT trial in newly diagnosed glioblastoma. The study tested starting Tumor Treating Fields (TTFields) at the beginning of chemoradiation versus starting during the maintenance phase.
The trial did not show a statistically significant improvement in the primary endpoint of overall survival for early initiation. Median overall survival in the intent-to-treat group was 17.7 months in the Early Start Arm versus 17.5 months in the Maintenance Start Arm (HR 0.953; p=0.519). One-, two- and three-year survival rates were similar between arms.
TTFields therapy, including initiation with chemoradiation, was well-tolerated with no new safety signals, and device-related safety remained consistent with prior TTFields studies in glioblastoma. Results have been accepted for presentation at the ASTRO 2026 Annual Meeting.
NovoCure Limited held its annual general meeting of shareholders, where investors re-elected eleven directors to serve until the 2027 meeting. Shareholders representing 93,826,730 ordinary shares, or approximately 81.01% of shares entitled to vote, were present in person or by proxy.
They approved the ratification of Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, as auditor for the fiscal year ending December 31, 2026, and supported executive compensation in a non-binding advisory vote. Shareholders also approved the Company’s Amended and Restated 2024 Omnibus Incentive Plan following a closely split vote between shares cast for and against.
NovoCure Ltd Chief Executive Officer Leonard Frank X reported a tax-related sale of 34,273 Ordinary Shares. The shares were sold in open-market transactions at a weighted average price of $17.9335 per share to cover tax withholding obligations arising from the vesting of Restricted Stock Units. According to the company’s equity incentive plan, this “sell to cover” transaction was mandated by the award agreement and is described as not representing a discretionary trade by the CEO. After these sales, Leonard Frank X directly holds 459,520 Ordinary Shares.
NovoCure Ltd director Gabriel Leung received new equity awards as part of compensation. He was granted 11,610 Ordinary Shares in the form of restricted stock units at no cost, increasing his direct holdings to 101,109 Ordinary Shares.
He also received stock options for 16,999 Ordinary Shares at an exercise price of $16.15 per share, expiring on June 3, 2036. Both the restricted stock units and the options are scheduled to vest 100% on the earlier of the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders.
NovoCure Ltd director Kristin Stafford received new equity awards. She was granted 11,610 ordinary shares in the form of restricted stock units at no cash cost, increasing her direct holdings to 22,934 ordinary shares.
She also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share. According to the award terms, the restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders. The options are scheduled to vest and become fully exercisable on the same timetable.
NovoCure Ltd director Allyson J. Ocean received new equity awards. She was granted 11,610 restricted stock units that will vest 100% on the earlier of the first anniversary of the grant or the day immediately preceding the company’s 2027 annual general meeting of shareholders.
She also received stock options for 16,999 ordinary shares at an exercise price of $16.15 per share, which will fully vest on the same schedule and expire on June 3, 2036. Following the restricted stock unit grant, she directly holds 22,934 ordinary shares.
NovoCure Ltd director Timothy J. Scannell received new equity awards as part of his compensation. On June 3, 2026, he was granted 11,610 restricted stock units and stock options for 16,999 ordinary shares at an exercise price of $16.15 per share.
The restricted stock units and options are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. After the restricted stock unit grant, Scannell directly holds 25,898 ordinary shares.
NovoCure Ltd director Jeryl L. Hilleman received new equity awards. On June 3, 2026, she was granted 11,610 Ordinary Shares as restricted stock units and 16,999 stock options with a $16.15 exercise price.
The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. The stock options follow the same vesting schedule and will become fully exercisable at that time. After the share grant, Hilleman directly holds 25,471 Ordinary Shares, and the option grant represents her reported derivative position in this filing.
NovoCure Ltd director David Hung reported receiving equity awards on ordinary shares. He was granted 11,610 restricted stock units, bringing his direct holdings to 32,075 ordinary shares after the award. He also received options for 16,999 ordinary shares at an exercise price of $16.1500 per share. The restricted stock units are scheduled to vest 100% on the earlier of the first anniversary of the grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders. The options are scheduled to fully vest and become exercisable on the same timetable, and will expire on June 3, 2036 if not exercised.